ReNeuron Group will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference.
ReNeuron researchers would describe studies undertaken to investigate the in vivo biodistribution of ExoPr0, using the most common and disease applicable routes of administration to deliver the exosomes.
"The studies showed that ExoPr0 can be targeted to specific organs and tissues by either local or systemic administration. The uptake of ExoPr0 by particular cell types in target organs suggests that there also may be some specificity in uptake at the cellular level," the company said.
ReNeuron said it had identified the potential of ExoPr0 as both a novel therapeutic candidate and as a drug delivery vehicle, based on earlier research to demonstrate the ability of ExoPr0 to modulate fibroblasts, immune cells and cancer cell lines in vitro.
This earlier work, together with these new findings showing that ExoPr0 can be targeted to specific tissues and organs and, most importantly, can penetrate the blood brain barrier, suggest that there is significant potential to develop ExoPr0 for the treatment of multiple diseases.
At 9:45am: (LON:RENE) ReNeuron Group PLC share price was 0p at 2.03p